Apart from the news about the progress of vaccination globally and by country (more on this at the end of the post), the main “vaccine” news concerns the Ad26.COV2.S vaccine from Johnson & Johnson (J&J). True, the vaccine is being developed by Janssen, which was absorbed by J & J, but retained its name. This creates some confusion – sometimes Ad26.COV2.S is called the J&J vaccine and sometimes the Janssen vaccine. As the name suggests, this vaccine is based on a human adenovirus type 26 vector.This non-replicating vector was “constructed” by Janssen specialists and they have a lot of experience working with this vector. Vaccine Ad26.COV2.S is a close relative of the 1st component of the GamCovidVac vaccine. In general terms, these are the same thing – a non-replicating vector Ad26 with an insert of a gene encoding the full-length S protein of the SARS-CoV-2 virus. A complete comparison is impossible due to the lack of detailed published information about the Ad26 vector and the insert coding for the S protein used in GamCovidVac. Be that as it may, the vaccination concepts for Ad26.COV2.S and GamCovidVacLight are the same – this is a single immunization with the possibility of “boost” in the future.
But there is also a difference. The vaccine Ad26.COV2.S was originally (starting with preclinical trials in monkeys) developed within the framework of this concept and a lot of data has already been accumulated on it precisely in the framework of a single immunization. As for GamCovidVacLight, the idea of such an application of GamCovidVac appeared recently and, although theoretically it is quite sensible, there is still very little concrete data in the context of a single immunization.Поділитися цим: